摘要
目的比较低剂量沙美特罗/氟替卡松干粉剂(SM/FP)与倍氯米松气雾剂(BDP)治疗成人咳嗽变异性哮喘的临床疗效和安全性。方法采用随机、开放、平行对照试验,选择118例14～68岁咳嗽变异性哮喘患者,按随机法分为试验组(60例,吸入SM/FP,1泡/次,每泡含沙美特罗50μg、氟替卡松干粉剂100μg,2次/d)和对照组(58例,吸入BDP,250μg/次,2次/d)。结果晨间呼气峰流速(PEFam):试验组60例患者在治疗第1周末全部恢复正常,而对照组只有70.7%(41/58)的患者恢复正常,4周时仍有6例(6/58,10.3%)PEFam低于正常,但大于预计值的80%(P<0.01);日间和夜间咳嗽症状积分:在试验组和对照组治疗第1周比较差异有统计学意义(P<0.01),4周时试验组下降的程度与对照组比较差异有统计学意义(P<0.01)。治疗期间两组患者血压、心率、心电图均无明显改变。两组患者不良事件的发生率比较差异无统计学意义(P>0.05)。结论联合吸入低剂量的FP和长效β2受体激动剂SM是控制咳嗽变异性哮喘的较好方法,加入低剂量的长效β2受体激动剂的疗效优于单一糖皮质激素。
Objective To compare the therapeutic effect and safety of low dose salmeterol/fluticasone propionate（SM/FP）inhalation and versus equivalent dose beclomethasone propionate（BDP）in treatment of adult cough variant asthma.Methods In a randomly,openlabe,parallel study,118 patients cases of adult cough variant asthma（14-68 years）were randomly divided into two groups.60 cases in experimental group（treated with SM/FP（50/100 μg）twice daily via Accuhaler）,58 cases in control group（treated with BDP 250μg twice daily via Turbuhaler）.The morning peak expiratory flow（PEFam）：The morning peak expiratory flow（PEFam）restored normal level after the first week in the 60 cases treated with SM/FP,but in the control group,only 70.7%（41/58）cases′PEFam restored normal level.After 4 weeks 6（6/58 10.3%）cases′PEFam was still below normal level,and greater than expectation value′s 80%（P〈0.01）;The significant benefit of SM/FP was evident from the firstweek（P〈0.01）.SM/FP led to a more significant reduction in the day-and night-time cough symptom scores,as compared to BDP（P〈0.01）.Both treatments were well tolerated,and the adverse reactions showed no significant difference between the two groups.Conclusions Use of low doses of SM/FP is a better choice for the control of adult cough variant asthma.The addition of a low-dose long-acting β2agonist is superior to the simple increase of the dosage of inhaled corticosteroids.
出处
《医学综述》
2010年第7期1117-1118,共2页
Medical Recapitulate
关键词
咳嗽变异性哮喘
吸入治疗
沙美特罗/丙酸氟替卡松
丙酸倍氯米松
Adult cough variant asthma
Inhalation therapy
Salmeterol/fluticasone propionate
Beclomethasone propionate
